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A mesofluidic multiplex immunosensor for detection
of circulating cytokeratin-positive cells in the blood
of breast cancer patients
François Breton & Bernard Bennetau &
Rosette Lidereau & Laurent Thomas & Gilles Regnier &
Jean-Claude Ehrhart & Patrick Tauc & Phuong-Lan Tran
Abstract We have recently reported the analytical perfor-
mance of an immunosensor comprising one mm-scale
parallel plate laminar flow chamber and applied to capture
MCF7 breast cancer cells (Ehrhart et al., Biosens. Bioelectr.
24, 467, 2008). Herein we present a new multiplex
immunosensor embodying four parallel plate laminar flow
chambers that fit onto a standard, functionalized, micros-
copy glass slide. The four surfaces are coated with long
alkyl chain spacers of 21-aminohenicosyl trichlorosilane
(AHTS) and then grafted with a monoclonal anti-human
epithelial cell adhesion molecule (EpCAM) antibody
specific of target cells to immobilize. We first demonstrate
a significantly (P<0.01) improved capacity of each of the
four flow chambers of the multiplex immunosensor to
capture MCF7 cells compared to the previous single
chamber device. Second, in addition to an increase of cell
immobilization, the multiplex device offers a versatile tool
easily grafted with various purified antibodies onto the four
surfaces. Third, we obtained high cell capture rate and
efficiency of various numbers of MCF7 cells spiked in
buffer containing an equal number of background leuko-
cytes. And fourth, we demonstrate isolation efficiency of
circulating tumor cells (CTCs) from peripheral blood drawn
from a small cohort of patients with localized or metastatic
breast cancer. This new multiplex immunosensor could be
tested for its potential to capture different subpopulations of
CTCs.
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1 Introduction
Metastasis in breast cancer patients leads to cancer-related
death as early spread of tumor cells usually remains
undetected at initial diagnosis on clinical, imaging, and
biochemical examination. Circulating tumor cells (CTCs)
are shed into blood circulation by both primary and
metastatic cancers, thus their detection in a blood sample
becomes of potential value despite their rarity (median,
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≤1 CTC/mL). Their isolation, enumeration and downstream
functional analyses could complement existing early detec-
tion methods and have clinical significance in preventing
long before the occurrence of overt metastasis. CTCs have
been successfully detected and isolated from blood in
patients with metastatic carcinomas (Allard et al. 2004) and
were associated with the disease progression (Cristofanilli
et al. 2004). A simple blood test would allow the detection
and analysis of CTCs to be frequently repeated. It would
also help to non-invasively stage the disease at diagnosis as
well as to monitor therapy and long-term patient manage-
ment (Cristofanilli et al. 2005; Hayes et al. 2006). Several
reports have shown that efficacy of treatment could be
measured by the number of CTCs in blood (Nolé et al.
2008; Tewes et al. 2009). CTCs provide easy access to
cancer patients for performing several molecular analyses.
Studies on alterations in CTC oncogenes suggested hetero-
geneity among cancer cells from a single patient, for
example with respect to heterogeneity of HER-2 and uPA
gene copy number and expression in breast cancer
(Cristofanilli and Mendelsohn 2006; Meng et al. 2004).
Thus identifying the CTC subpopulations contained in a
blood sample could help identifying targets for treatment
and exploring mechanisms that underlie metastases and
drug sensitivity. Increasing useful information on CTCs
might help to tailor systemic therapies to the individual
needs of a cancer patient.
The detection and isolation of rare CTCs in the blood of
patients encountered tremendous technical challenges
(Kahn et al. 2004; Krivacic et al. 2004; Racila et al. 1998;
Zieglschmid et al. 2005). The most currently used methods
for CTC quantitative detection include immunomagnetic
separation followed by immunocytochemistry detection
(Allard et al. 2004; Cristofanilli et al. 2004; Riethdorf et
al. 2007; Talasaz et al. 2009) or RT-PCR to indicate the
qualitative presence of CTCs in peripheral blood (Aerts et
al. 2001; Iakovlev et al. 2008; Schröder et al. 2003). CTCs
isolated by immunomagnetic beads coated with antibodies
against the epithelial cell adhesion molecule (EpCAM) are
identified by cytokeratin-positivity, DAPI nuclear staining
and CD45 negativity. Other techniques such as cell
filtration (Kahn et al. 2004; Wong et al. 2006) and flow
cytometry (Allan et al. 2005; Cruz et al. 2005) have also
been used to isolate and enumerate CTCs in blood samples.
Alternative methodologies as regards to successful
isolation of viable cells, reduction of the treated blood
sample volume and hands-on processing time were dealt
with microfluidic procedures. CTC detection is performed
on the so-called CTC-Chips made within a 967-mm2
surface of 78,000 functionalized microposts coated with
anti-EpCAM antibodies (Nagrath et al. 2007), in a biochip
consisting of microchannels also coated with anti-EpCAM
antibodies (Du et al. 2007), or in a label-free microdevice
separating CTCs from blood constituents on biorheological
property differences (Tan et al. 2009). Most existing
techniques are associated with protocols that allow captur-
ing only cancer EpCAM-positive epithelial cell population
in peripheral blood. This could be a limiting factor and
leads to missing information on cancer EpCAM-negative
cell subpopulations if more than one cancer cell subpopu-
lations are present (Sieuwerts et al. 2009). Therefore an
advanced tool for detection of various breast cancer cell
subpopulations for “tailored” therapy should be investigated
(Cristofanilli and Braun 2010).
We recently developed a new immunosensor for breast
cancer cell detection that provided improved yield of
captured MCF7 breast cancer cells spiked in background
leukocytes, using a parallel plate laminar flow mm-scale
chamber for fluid circulation. Design of the flow chamber at
a mm-scale, hence the so-called mesofluidic designation,
enables to reduce the rheological phenomena not yet well
mastered in microfluidics. The surface floor is functionalized
by grafting long alkyl chain spacers of 21-aminohenicosyl
trichlorosilane (AHTS) followed by tethering a monoclonal
anti-human epithelial cell adhesion molecule (EpCAM)
antibody (Ehrhart et al. 2008; Tran and Bennetau 2004).
The flow kinetics of the immunosensor is optimized for
minimal shear forces and maximal contact between cells
and the active surface. To further improve cell capture rate
and efficiency of this mesofluidic device, we describe
herein the performance of a new multiplex immunosensor
embodying in parallel four parallel plate laminar flow
chambers that fit onto a standard, functionalized, microsco-
py glass slide, with the ultimate goal of applying this
methodology in a future clinical setting.
2 Materials and methods
2.1 Glass surface silanization and antibody coupling
Glass substrate and silane film preparation were performed
as previously described (Ehrhart et al. 2008; Martin et al.
2005). Standard microscopy glass slides were first silanized
under Ar atmosphere with N-protected AHTS [N-(21-
trichlorosilanylhenicosyl)-phthalimide], then deprotection
of the amino group of AHTS (21-aminohenicosyl trichlor-
osilane) was performed as described (Bennetau et al. 2000;
Ehrhart et al. 2008; Martin et al. 2005).
Antibody immobilization on the silane-coated glass
surface was performed with the monoclonal anti-human
EpCAM antibody or the monoclonal anti-human erbB2
antibody (R&D Systems, Lille, France) in MES-buffered
saline (2-[morpholino]ethanesulfonic acid), 0.09% NaCl,
pH 4.7 (Perbio Science, Brebières, France) at a concentra-
tion of 1 mg/mL in the presence of 1-ethyl-3-(3-dimethy-
laminopropyl) carbodiimide hydrochloride (EDC, Perbio
Science) overnight at 4°C. All slides were then washed in
PBS and stored at 4°C under Ar atmosphere up to 2 weeks
until use. In negative controls, AHTS-coated surfaces were
grafted with the monoclonal anti-human CD3 antibody,
specific to T lymphocytes but non-specific to MCF7 cells
(Dako, France). Quality controls were performed as
described (Ehrhart et al. 2008).
2.2 Characteristics of laminar flow in a multiplex
embodying four parallel plate laminar flow chambers
The physical characteristics of a single parallel plate
laminar flow chamber of dimensions 6×16×0.5 mm3
(W × L × H) were previously described (Ehrhart et al.
2008). To largely increase the cell capture surface, a new
device was designed that consisted of a multiplex embody-
ing four parallel plate laminar flow chambers (Tran et al.
patent filed 2009). This device was made of a poly(methyl
methacrylate) (PMMA) block bearing four cavities, each of
dimensions 6×16×0.5 mm3 (W × L × H), and sealed by a
polydimethylsiloxane (PDMS) gasket against a standard
microscopy glass slide [26×76 mm2 (W × L)].
Figure 1 displays the simulation of progressive fluid
filling of the four chambers. The circulating flow was
supplied through a single channel to the entrance of the four
laminar flow chambers, and the outlet of each chamber was
connected to the channel of a peristaltic pump (Ismatec,
Glattbrugg, Switzerland).
According to the geometry of the flow chamber, a model
was constructed using the “incompressible Navier-Stokes”
hypothesis of Molflow® Insight software (MPI 6.1 revision
5, Autodesk®, USA). The mesh applied was obtained using
the automatic mesh tool Hypermesh V8 leading to
tetrahedron meshes with three nodes per side. The
parameters used for this particular simulation were as
follows: 1) the viscosity of water was 1.0×10−3 Pa.s at
20°C; 2) the fluid flow near the wall equals 0; 3) a flow rate
of 90 μL/min applied at the inlet was resolved as a flow
rate of 22.5 μL/min per chamber, and the outlets were
considered as free under atmospheric pressure. The flow in
the chambers is laminar because of the low Reynolds
number calculated in a suitable unit system as follows:
Re ¼ 1:67 105  Qlh , where Q is the flow rate (μL/min),
l the flow chamber width (mm), and η the fluid viscosity
(Pa.s) (Richter et al. 1997). Re=0.0625, when a flow rate of
22.5 μL/min of water at 20°C was applied to a 6-mm width
flow chamber. Laminar flow rate ranging from 20 μL/min
to 1,000 μL/min was simulated using Molflow® Insight
software and led to the same figure. A reduction to a
minimum dead volume at the entrance of the flow chambers
was achieved and led to rapid cell contact with the
functionalized glass surfaces.
2.3 Patient eligibility
Patients eligible for this study were diagnosed with a
localized breast carcinoma or with a metastatic adenocarci-
noma of the breast (Centre René Huguenin, Saint-Cloud,
France). The patient record was reviewed only to confirm the
disease status, and no information on treatments or clinical
course in the case of metastatic disease was abstracted.
Patients gave verbal consent to donate 15 mL of blood
for this research study. All blood samples were drawn into
Li heparinate Vacutainer tubes (Becton Dickinson, Pont de
Claix, France). They were diluted into RPMI (Roswell Park
Memorial Institute) medium containing 10% fetal calf
serum (FCS), 2 mM glutamine, 100 U/mL penicillin and
100 μg/mL streptomycin (Gibco BRL, Gaithersburg, MD,
USA). Ficoll-Hypaque density gradient centrifugation was
then performed at 1,600×g for 20 min at 15°C. The entire
volume of the compartment with interphase leukocyte cells
was poured into a fresh centrifugation tube. Cells were
centrifuged with washing buffer at 200×g for 10 min at
4°C. Cells were then frozen in complete RPMI medium
containing 10% DMSO (dimethylsulfoxide) in liquid N2 for
subsequent cell capture experiments.
Fresh blood samples from healthy volunteers were used
as controls. Four mL of blood were drawn into heparin plus
EDTA (ethyldiaminetetraacetic acid) Vacutainer tubes
(Becton Dickinson, Pont de Claix, France). They were
diluted into complete RPMI medium as described above
and isolation of nucleated leukocyte cells was performed
onto ACCUSPIN tubes (Sigma-Aldrich, Saint Quentin
Fallavier, France) at 1,600×g for 20 min at 15°C. They
were washed with Hanks balanced salt solution (HBSS),
:
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Fig. 1 Outline of the mesofluidic multiplex device embodying four
parallel plate laminar flow chambers (Tran et al. patent filed 2009). A
simulation of progressive fluid filling of the four mm-scale chambers
is displayed. A flow rate of 90 μL/min was applied at the inlet, which
was resolved as a flow rate of 22.5 μL/min per chamber. Each outlet
was connected to the channel of a peristaltic pump and considered as
free under atmospheric pressure. The pseudocolour progression from
blue to red represents the progressive water filling
and resuspended in HBSS plus 0.3% human serum albumin
(HSA, Sigma-Aldrich) to a dilution of 10×106 cells/mL.
2.4 Cell isolation in single and multiplex parallel plate
laminar flow chambers
The human breast cancer MCF7 cell line used herein
underwent long-term passages (>70), thus gaining high
expression of HER2 (Wang and Wang 2010). Cells were
grown in DMEM (Dulbecco’s Modified Eagle Medium,
Gibco BRL) containing 10% FCS, 2 mM glutamine,
100 U/mL penicillin and 100 μg/mL streptomycin, and
cultured until subconfluence. They were then detached,
washed with HBSS and resuspended in HBSS plus 0.3%
HSA to a dilution of 2×106 cells/mL. They were then
loaded in the multiplex onto four AHTS-coated glass
surface grafted with the monoclonal anti-human EpCAM
antibody, or in subsequent experiments using two anti-
bodies onto two AHTS-coated glass surface grafted with
the monoclonal anti-human EpCAM antibody and two
AHTS-coated glass surface grafted with the monoclonal
anti-human erbB2 antibody. Negative controls were per-
formed with cells loaded onto two AHTS-coated glass
surfaces alone and two AHTS-coated glass surfaces grafted
with the monoclonal anti-human CD3 antibody specific to
T lymphocytes but non-specific to MCF7 cells.
Optimization of cell capture was performed by running in
parallel four single parallel plate laminar flow chambers,
compared to the multiplex immunosensor embodying four
parallel plate laminar flow chambers. We first validated the
experimental criteria of the new multiplex device using
MCF7 breast cancer cells spiked in buffer containing 10×
106 leukocytes/mL, as reported above. Dilutions of MCF7
cells varied from 10 to 2,000 MCF7 cells/mL. As
previously described for a single chamber (Ehrhart et al.
2008), the following parameters were specified for the
multiplex device. A flow rate of 90 μL/min was applied at
the inlet, which was resolved as a flow rate of 22.5 μL/min
per chamber for driving cells into the flow chambers, until
the entire active surface was covered. Then 12-min cell
incubation was performed at room temperature under stable
conditions. At the end of the incubation period, non-
specifically bound cells were flushed with PBS at the same
flow rate of 22.5 μL/min per chamber for 6 min. In another
experiment with MCF7 cells, concomitant grafting of the
surface floors of the multiplex with two different antibodies
was also performed: two surfaces received the monoclonal
anti-human erbB2 antibody, and the two remaining surfaces
the monoclonal anti-human EpCAM antibody. Cell count-
ing of all slides was performed with MATLAB software
(Ehrhart et al. 2008).
Next, frozen blood samples from cancer patients and
fresh blood samples from healthy donors were routinely
tested using the multiplex device: blood samples from 21
patients with metastatic breast cancer, 11 patients with
localized breast cancer and 16 healthy donors. The floor
surfaces of the four flow chambers were coated with the
monoclonal anti-human EpCAM antibody. No more extra
blood samples were available for an experiment in which
two surfaces could have been grafted with the anti-human
EpCAM antibody and two others with the anti-erbB2
antibody. The parameters applied for isolation of CTCs
were as described above. Non-specifically bound cells were
flushed with PBS at the same flow rate of 22.5 μL/min per
chamber for 6 min.
2.5 Immunofluorescence staining and identification
of CTCs by fluorescence microscopy
Following release of the glass slide from the multiplex
device, cells were fixed with 100 μL cold acetone. Cell
labelling was processed with subsequent various cell
markers, as previously reported (Ehrhart et al. 2008). Briefly,
MCF7 cells and CTCs from human blood samples were
labelled by the primary polyclonal anti-pan-cytokeratin
antibody and leukocytes either by anti-CD45 allophycocya-
nin (APC)-conjugated IgG, or a panel of anti-CD3, -CD20
and -CD35 antibodies (Dako, France), followed by second-
ary anti-rabbit Alexa-conjugated IgG and anti-mouse Alexa-
conjugated IgG (Molecular Probes—Invitrogen, France),
respectively, according to Tran et al. (1996). Cell nuclei
were labelled with DAPI (1 μg/mL) for 5 min.
All slides were analyzed on an inverted NIKON E50i
(NIKON, France) microscope equipped with an automated
stage (IMSTAR, France). Each slide containing four capture
surfaces was scanned automatically in a 1360×1024 pixels
format using the programmable stage and capture software
(version 6, imaging IMSTAR systems, France). Captured
images at 10×magnification were carefully examined and the
objects that met predetermined criteria were counted. Colour,
brightness and morphologic characteristics such as cell size,
shape and nuclear size were considered in identifying
potential tumor cells, MCF7 or CTCs, excluding cell debris,
non-specific and false positive cells. The criteria for their
selection were as follows: cells that stained positive by the
primary polyclonal anti-pan-cytokeratin antibody and sec-
ondary Alexa-conjugated anti-rabbit IgG (green fluores-
cence) and met the phenotypic morphological
characteristics were scored as MCF7 or CTCs; the same cells
were stained by DAPI (blue stain) and negatively stained by
anti-CD45-APC or anti-CD3, -CD20 and -CD35 and Alexa-
conjugated anti-mouse IgG (no red fluorescence).
2.6 Statistical analysis
All data were analyzed using a paired Student’s t-test.
3 Results and discussion
3.1 Improvement of MCF7 breast cancer cell capture
by each chamber of the multiplex immunosensor
The new multiplex device is fabricated in a unique PMMA
piece embodying four mm-scale chambers that fits onto a
standard microscopy glass slide (Section 2). Figure 1 outlines
such a device showing fluid flow through the four laminar
flow chambers (Tran et al. patent filed 2009). According to
this design, a minimum dead volume produced at the
entrance of the four chambers allows a rapid access of tumor
cells to the four glass surfaces. These surfaces are
functionalized by coating with long amino-silane AHTS
chains followed by grafting with the monoclonal anti-human
EpCAM antibody (Section 2).
The results displayed in Table 1 demonstrate an
enhanced immobilization of MCF7 breast cancer cells onto
the functionalized glass surfaces. A mean cell capture yield
of 6391±247 MCF7 cells per chamber in the multiplex was
achieved, versus cell capture yield of 3435±233 MCF7
cells in a single laminar flow chamber (Table 1, and Ehrhart
et al. 2008). Comparing cell capture yielded by each
chamber of the multiplex device to that of a single chamber,
a significant difference was observed (P<0.01) owing to
the design of new characteristics that minimized loss of
tumor cells in the dead volume.
3.2 Versatility of antibody grafting
Unlike a single parallel plate laminar flow chamber whereof
the silanized surface was grafted with either the monoclonal
Table 1 Significant improvement (P<0.01) of MCF7 cell capture by each chamber of the multiplex device compared to that previously
observed (aEhrhart et al. 2008) with a single chamber. In both conditions, capture was performed on AHTS-coated surface glass slides grafted
with the anti-human EpCAM monoclonal antibody. Control surfaces reflect the amount of non-specific adsorption when anti-EpCAM was
absent from the silane-grafted surfaces. Cell count results were obtained from three independent experiments. Values were reported as the
mean±S.D
Single flow chamber Multiplex embodying four flow chambers
Chamber #1 Chamber #2 Chamber #3 Chamber #4
Cell counts for control surfaces 223±74a 280±65 305±56 292±71 325±95
Cell counts for AHTS-coated + anti-EpCAM-grafted surfaces 3435±233a 6049±333 6433±245 6338±352 6742±410
ificant improvement (P<0. 1) of MCF7 cell capture by
each chamber of he multiplex device compared to that previ usly
observed (aEhrhart et al. 2008) with single chambe . In both
conditions, capture was performed on AHTS-coated surfac glass
slides grafted with the anti-human EpCAM monoclonal antibody.
Control surfaces reflect the amount of n n-specific adsorption when
anti-EpCAM was abs nt from the sil ne-grafted surfaces. Cell count
results were obtained from three independent experiments. Value
we e repo ted as th m an±S.D
Table 2 Comparison of MCF7 cell capture counts on four AHTS-
coated surfaces of the multiplex grafted with two different antibodies.
Two surfaces were grafted with the anti-human erbB2 monoclonal
antibody and two other surfaces with the anti-human epithelial cell
adhesion molecule (EpCAM) monoclonal antibody. Cell count results
were obtained from three independent experiments. The difference
between MCF7 counts on both functionalized surfaces (P<0.05) could
be attributed to a difference in expressed erbB2 and EpCAM. Values
were reported as the mean±S.D
Multiplex four flow chambers
AHTS-coated + anti-
erbB2-grafted surfaces
AHTS-coated + anti-
EpCAM-grafted surfaces
Chamber #1 Chamber #2 Chamber #3 Chamber #4
Cell counts 5044±167 5055±112 5710±111 5890±114
Fig. 2 (a) and (b) Regression analyses of MCF7 cell capture
efficiency in single (a) and multiplex (b) parallel plate laminar flow
chambers. The plots represent the number of MCF7 breast cancer cells
spiked in 10×106 leukocytes/mL versus the number of MCF7 cells
recovered
anti-human EpCAM antibody or the monoclonal anti-
human erbB2 antibody (Ehrhart et al. 2008), the multiplex
device sealed with a standard microscopy glass slide coated
with long amino-silane AHTS chains allows simultaneous
grafting of several antibodies. Therefore one to four
different antibodies can be grafted on each AHTS-coated
surface. Accordingly, the monoclonal anti-human EpCAM
antibody was grafted along with the monoclonal anti-
human erbB2 antibody, each antibody separately in
duplicate onto two AHTS-coated surfaces. Since previous
results showed the same cell distribution within and
between the four chambers of the multiplex device, the
order of antibodies grafting on each of the four surfaces for
capturing cells expressing various surface antigens should
not have any impact on cell immobilization efficiency. We
took advantage of this new procedure and flowed MCF7
cells from a unique sample source (Section 2) onto
differentially functionalized glass surfaces. Table 2 displays
the results on MCF7 cell counts obtained with a combina-
tion of two by two antibody-grafted surfaces. The differ-
ence observed between MCF7 cell counts in surfaces
functionalized with anti-erbB2 antibodies and that with
anti-EpCAM antibodies, 5050±140 versus 5800±113 (P<
0.01), respectively, could be due to a difference with respect
to their number of expressed receptors. Negative controls of
AHTS-coated surfaces without grafting any antibody or
grafted with the monoclonal anti-human CD3 antibody,
non-specific to MCF7 cells, reflected the amount of non-
specific adsorption in the absence of the monoclonal anti-
EpCAM and anti-erbB2 antibodies. Cell counts from three
independent experiments yielded 415±107 for AHTS-
coated surfaces alone, and 333±70 for AHTS-coated
surfaces grafted with the monoclonal anti-CD3 antibody.
Hence, the multiplex device could be a potential tool for the
detection of subpopulations of CTCs expressing various
tumor cell markers.
3.3 Cell capture rate and efficiency
To evaluate tumor cell capture under physiologic con-
ditions, we compared the capture of MCF7 human breast
cancer cells spiked in blood from healthy donors by the
four chambers of the multiplex to that of a single chamber.
Both devices carried AHTS-coated surfaces grafted with
the monoclonal anti-human EpCAM antibody. As described
in Section 2, a series of various cell suspensions was
performed at concentrations ranging from 10 to 2,000
tumor cells per mL of buffer containing 10×106 leukocytes.
Immobilized cells were then submitted to staining of MCF7
cells and leukocytes and analysis for cell recovery yield
(see Section 2). In cell capture experiments using a single
chamber, each cell suspension concentration was loaded in
a volume of 48 μL. Figure 2(a) displays the numbers of the
MCF7 cells recovered per single chamber. In the multiplex
including four chambers, each cell concentration was
resuspended in a total volume of 4×48 μL, therefore the
Fig. 3 CTC identification. High
magnification (20×) images of
captured CTCs and haemato-
logic cells from a breast cancer
patient. Nuclei were stained with
DAPI (a). A CTC is positively
stained with the anti-pan-
cytokeratin antibody and a
secondary anti-rabbit Alexa-
conjugated IgG. Haematologic
cells were stained with anti-
CD3, -CD20 and -CD35
antibodies and a secondary anti-
mouse Texas Red-conjugated
IgG. Merge image (d), arrow
and insert, identifies a CTC
stained positive for cytokeratin
(b), and negative for haemato-
logic cell markers (c)
results were expressed as a total number of recovered cells
(Fig. 2(b)). Figure 2, (a and b), depicts a regression analysis
of capture efficiency for various target cell concentrations
in both devices. The recovery rate yielded from 70% to
90% in both cases. Capture rates were comparable under
both conditions: y=0.9873x − 0.0371 (R=0.99911) and
y=1.0365x − 0.1064 (R=0.99652), respectively. In addi-
tion to high capture rates of targeted cells, only 1.8 (±1)%
of background leukocytes are observed on the capture
surfaces. When compared to the recovery rate of targeted
cell capture of 70–90%, this depletion level of background
cells demonstrates high capture specificity and sensitivity
of our device. As expected (Table 1; Fig. 2(b)), the
multiplex significantly increased the total number of
detected MCF7 cells spiked in normal blood on the four
functionalized surfaces (P<0.01). This important charac-
teristic will provide an advantageous performance when
capture of various tumor cell subpopulations per multiplex
will be required.
3.4 Isolation of CTCs from breast cancer patients’ blood
We tested the capacity of the multiplex to capture CTCs
from blood samples provided by cancer patients. A total
of 128 samples from 32 patients with epithelial breast
cancers and 16 healthy donors were studied. Blood
specimens were collected from 21 patients with metastatic
disease, 11 patients with localized disease and 16 healthy
donors as controls.
Identification of CTCs on each surface capture of the
multiplex consisted of staining with 4,6-diamino-2-phe-
nylindole (DAPI) for DNA content, anti-pan-cytokeratin
antibodies for epithelial cells, and either anti-CD45 or a
cocktail of anti-CD3, -CD20, -CD35 antibodies for
haematologic cells (Fig. 3(a–d)). Captured cells staining
positive for cytokeratin and negative for haematologic
markers were recorded as CTCs. The morphologic charac-
teristics exhibited by the captured CTCs were consistent
with malignant cells, including large cellular size with high
nuclear:cytoplasmic ratios (Fig. 3(d) and insert). The cell
viability of captured cells was assessed under transmission
light using Trypan blue that attested integrity of the cell
membrane.
Table 3 displays the number of blood specimens tested
for CTCs from patients with localized breast cancer and
patients with metastatic breast cancer. All blood samples
from breast cancer patients were analyzed in triplicate and
that from healthy donors in duplicate. The number of CTCs
ranged from 8 to 103 per 5 mL (39±24, mean±S.D.;
median, 38) for metastatic breast cancer and 0 to 5 (0.8±
1.5, mean±S.D.; median, 0) among localized breast cancer.
None of the 16 healthy donor blood samples had any
identifiable CTC. The patient groups in Table 3 are sorted
according to the frequency of patients with >0 CTC. The
number and percentage of blood specimens with >0, ≥5,
≥10, ≥20, ≥30, ≥50 CTCs in 5 mL are provided. The
sensitivity of our technique enabled identification of CTCs
in three patients with localized breast cancer (3/11, 27%)
and 100% of the 21 patients with metastatic disease showed
Table 3 Summary of CTC counts in 5 mL of blood from breast
cancer patients and healthy donors. All blood samples from breast
cancer patients were analyzed in triplicate and that from healthy
donors in duplicate. The patient groups are sorted according to the
frequency of patients with >0 CTC. The number and percentage of
blood specimens with >0, ≥5, ≥10, ≥20, ≥30, ≥50 CTCs in 5 mL are
also provided. The sensitivity of our technique enabled identification
of CTCs in three patients with localized breast cancer and 100% of the
21 patients with metastatic disease showed significant levels of CTCs
(≥8 CTCs/5 mL)
Subjects No. of
patients
No. of analyzed
specimens
Range Mean
±SD
Median No.
(%) >0
No. (%)
≥5
No. (%)
≥10
No. (%)
≥20
No. (%)
≥30
No. (%)
≥50
Healthy 16 32 0–0 0±0 0 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Localized breast cancer 11 33 0–5 0.8±1.5 0 3 (27) 1 (9) 0 (0) 0 (0) 0 (0) 0 (0)
Metastatic breast cancer 21 63 8–103 39±24 38 21 (100) 21 (100) 19 (90) 16 (76) 12 (57) 6 (29)
Fig. 4 Prevalence of CTCs in 5 mL of blood from breast cancer
patients and healthy donors. All blood samples were processed as
described in Section 2. CTC captures were performed on glass slides
coated with long amino-silane chains, AHTS, and grafted with the
anti-human EpCAM antibody using the multiplex immunosensor
embodying four parallel plate laminar flow chambers. (a) frequency of
CTCs per 5 mL blood sample in patients with metastatic breast cancer
(red circle). (b) frequency of CTCs per 5 mL blood sample in patients
with localized breast cancer (blue square). (c) absence of CTCs per
5 mL blood sample in control healthy donors (green square)
significant levels of CTCs (≥8 CTCs/5 mL). A clear
difference between numbers of CTCs detected in the groups
of metastatic breast cancer and those of localized breast
cancer demonstrated high sensitivity and selectivity pro-
vided by functionalized glass surfaces coated with long
alkylsilane chains AHTS and grafted with purified anti-
human EpCAM antibody (Fig. 4).
4 Conclusion
Designing a mesofluidic strategy with four parallel plate
laminar flow chambers aims optimization at a mm-scale of
the detection of rare cells in a complex body fluid. That
procedure enables higher detection sensitivity due to
lower dead volume, reduction in rheological phenomena
not yet well mastered in microfluidics, and the design of a
user-friendly and non-invasive medical device for in vitro
diagnosis (Tran and Bennetau 2004; Tran et al. 2009). Here
we demonstrate the analytical performance of this new
immunosensor applied to gently immobilize breast cancer
CTCs utilizing antibody grafted on long alkylsilane-coated
glass surface. The device allows high sensitivity and
specificity for capture and purification of large numbers
of viable CTCs. Additional to an optimization of CTC
immobilization, the multiplex immunosensor offers a
versatile tool readily grafted with various purified anti-
bodies. The surfaces of such a device can be grafted with
up to four different purified antibodies, enabling the
potential detection of various subpopulations of CTCs.
Another important feature of the multiplex immunosensor
is its active glass surface that provides an ideal transparent
surface easy to read under fluorescence microscopy. Then
recovered glass surfaces can be easily processed for further
cellular, genetic and biochemical analyses. To the best of
our knowledge, this is the first tool that allows performing
various protocols from cell immobilization on a function-
alized glass slide to downstream analyses on the same
stand.
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